



Medicine Supply Notification

MSN/2024/064

Somatropin (NutropinAq[®]) 10mg/2ml solution for injection cartridges
Somatropin (Humatrope[®]) 6mg, 12mg and 24mg powder and solvent for solution for injection cartridges

Tier 2 – medium impact*

Date of issue: 29/05/2024

Link: [Medicines Supply Tool](#)

Summary

- Somatropin (NutropinAq[®]) 10mg/2ml solution for injection cartridges have been discontinued with stock exhausted late March 2024.
- Somatropin (Humatrope[®]) 6mg, 12mg and 24mg powder and solvent for solution for injection cartridges have been discontinued with stock exhausted late April 2024.
- Other brands of somatropin remain available and can support increased demand.

Actions Required

Secondary care pharmacy teams should work with clinical specialists and their local pharmacy homecare lead to:

- ensure patients are not initiated on NutropinAq[®] or Humatrope[®] products;
- review patients currently prescribed NutropinAq[®] and Humatrope[®] products, including those in shared care arrangements, and issue a new prescription for an alternative somatropin product (see Supporting information);
- ensure all new prescriptions are sent to patient's current homecare service provider or outpatient dispensary;
- communicate with home care providers if nurse led injection training is required on the new prescription.

Homecare providers should:

- ensure that once a new prescription is received, the patient's existing NutropinAq[®] or Humatrope[®] prescription is immediately cancelled;
- call patients to inform them of the change to their prescription while arranging delivery and offer nursing support and counselling on the change in device; and
- work with the prescriber and the Trust homecare lead to ensure nurse led training or, if available, drug administration support, is offered where requested.

Outpatient pharmacies should ensure that:

- once a new prescription is received, the patient's existing NutropinAq[®] or Humatrope[®] prescription is cancelled;

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

- patients receive a patient education pack and are counselled about the change in prescription at the point of first dispensing; and
- patients are directed back to their specialist team if they require additional nurse-led training or ongoing nursing support.

GP surgeries who prescribe NutropinAq® and Humatrope® should:

- proactively identify all patients on these treatments and refer them to their specialist prescribing centre for review and switching to alternative somatropin products.

Supporting information

Clinical Information

No additional monitoring is anticipated following a change to an alternative somatropin product but the change in device requires patients and/or their carers to be counselled on how to use the new device and ensure the correct dose is administered.

Table of somatropin products

Brand	Presentation	Strengths	Licensed indications	Excipient with known effects
NutropinAq®	Solution for injection cartridge	10mg/2ml	Children: Growth disturbance related to insufficient growth hormone secretion, Turner syndrome, chronic renal insufficiency Adults: Replacement therapy in adults with pronounced growth hormone deficiency.	Contains phenol and citric acid
Humatrope®	Powder and solvent for solution for injection cartridge	6mg, 12mg, 24mg	Children: Growth disturbance related to insufficient growth hormone secretion, Turner syndrome, chronic renal insufficiency, SHOX deficiency, growth disturbance in short children born small for gestational age Adults: Replacement therapy in adults with pronounced growth hormone deficiency.	Contains mannitol
*Omnitrope®	Solution for injection cartridge- Pen/SurePal	5mg/1.5ml, 10mg/1.5ml, 15mg/1.5ml	Children: Growth disturbance related to insufficient growth hormone secretion, Turner syndrome, chronic renal insufficiency, growth disturbance in short children born small for gestational age and Prader-Willi syndrome Adults: Replacement therapy in adults with pronounced	Contains phenol

			growth hormone deficiency.	
*Genotropin®	Powder and solvent for solution for injection – pre-filled disposable device, cartridge	MiniQuick: 400microgram, 600microgram, 800microgram, 1mg, 1.2mg, 1.4mg, 1.6mg, 1.8mg, 2mg Cartridge: 5.3mg, 12mg, GoQuick pen: 5.3mg, 12mg,	As for Omnitrope®	Contains mannitol
*Saizen®	Solution for injection cartridge	6mg/1.03ml, 12mg/1.5ml, 20mg/2.5ml,	As for Omnitrope®	Contains citric acid and phenol
*Zomacton®	Powder and solvent for solution for injection	4mg	Children: Growth disturbance related to insufficient growth hormone secretion and Turner syndrome	Solvent contains benzyl alcohol, powder contains mannitol
Norditropin Flexpro®	Solution for injection pre-filled pens	5mg/1.5ml, 10mg/1.5ml, 15mg/1.5ml	Children: Growth disturbance related to insufficient growth hormone secretion, Turner syndrome, chronic renal insufficiency, growth disturbance in short children born small for gestational age and Noonan syndrome. Adults: Childhood onset and adult onset growth hormone deficiency	Contains phenol and mannitol

*Omnitrope®, Genotropin®, Saizen®, Zomacton® and Norditropin Flexpro® (10mg/1.5ml and 15mg/1.5ml) are available

Note: Genotropin® MiniQuick 200microgram and Norditropin Flexpro® 5mg/1.5ml remain available but are unable to support an uplift.

[Links to further information](#)

- [SmPC NutropinAq®](#)
- [SmPC Humatrope](#)
- [SmPC Omnitrope®](#)
- [SmPC Norditropin FlexPro®](#)

- [SmPC Genotropin®](#)
- [SmPC Saizen®](#)
- [SmPC Zomacton®](#)
- [BNF Somatropin](#)

Enquiries

Enquiries from NHS Trusts in England should in the first instance be directed to your Regional Pharmacy Procurement Specialist (RPPS) or Associate RPPS, who will escalate to national teams if required.

REGION	Lead RPPS	Email	Associate RPPS	Email
Midlands	Andi Swain	andi.swain@nhs.net	vacant	
East of England	James Kent	james.kent@nhs.net	Tracy McMillan	tracy.mcmillan2@nhs.net
London	Jackie Eastwood	jacqueline.eastwood@gstt.nhs.uk	Daniel Johnson	Daniel.Johnson@gstt.nhs.uk
North East and Yorkshire	David Allwood	davidallwood@nhs.net	Penny Daynes	penny.daynes@nhs.net
North West	Richard Bateman	richard.bateman@liverpoolft.nhs.uk	Andy Stewart	Andrew.stewart@liverpoolft.nhs.uk
South East	Alison Ashman	Alison.Ashman@berkshire.nhs.uk	Melanie Renney	melanie.renney@berkshire.nhs.uk
South West	Danny Palmer	danny.palmer@uhbw.nhs.uk	Natalie Bryson	Natalie.Bryson@uhbw.nhs.uk

Scotland

nss.nhssmedicineshortages@nhs.scot

Wales

MedicinesShortages@gov.wales

Northern Ireland

RPHPS.Admin@northerntrust.hscni.net

All other organisations should send enquiries about this notice to the DHSC Medicine Supply Team quoting reference number MSN/2024/064.

Email: DHSCmedicinesupplyteam@dhsc.gov.uk.